Biotechnology

Antengene Announces First Patient Dosed in the PROBE-CN Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma

* ATG-101 is a novel PD-L1/4-1BB bispecific antibody. It is Antengene's first in-house developed molecule with global rights. *  ATG-101 demonstrates potent in vivo efficacy in anti-PD-1/PD-L1 resistant mouse tumor models. SHANGHAI and HONG KONG, Aug. 3, 2022 /PRNewswire/ -- Antengene Corpora...

2022-08-03 08:30 1855

Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

Preclinical data support the potential of ONA-XR plus estrogen receptor degraders in endocrine resistant disease models Context to initiate Phase 1b/2 clinical trial in Q4 2022 PHILADELPHIA and FLORENCE, Italy, Aug. 2, 2022 /PRNewswire/ -- Context Therapeutics Inc. ("Context" or the "Company") (...

2022-08-02 22:49 2528

Metabolon Awarded ISO 9001:2015 Recertification

ISO 9001:2015 certificate re-issued to Metabolon following continued demonstrated ability to meet customer, statutory, and regulatory standards MORRISVILLE, N.C., Aug. 2, 2022 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance drug development and ...

2022-08-02 20:57 1587

Sironax Announces Closing of $200 Million Series B Financing

Financing from new and existing investors will support pipeline progression and expansion for age-related degenerative diseases BEIJING, Aug. 2, 2022 /PRNewswire/ -- Sironax, an emerging biotechnology company dedicated to the discovery and global development of novel treatments for patients with...

2022-08-02 19:00 1946

Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency

Implemented by the Centers for Disease Control and Prevention, the diagnosis code will accurately identify US patients with APDS, supporting care and research efforts LEIDEN, Netherlands, Aug. 2, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Na...

2022-08-02 13:00 2013

Advanced Instruments Acquires SAL Scientific, Expertise, and a Range of Cell Growth Supplements in Support of Research & Drug Discovery Workflows

NORWOOD, Mass., Aug. 2, 2022 /PRNewswire/ -- Advanced Instruments, a leading manufacturer of analytical instruments and services for bioprocessing, today announced the acquisition of SAL Scientific Ltd., a private company that develops and manufactures a portfolio of cell growth supplements for C...

2022-08-02 10:28 1850

GenKOre develops hypercompact adenine base editors (ABEs)

DAEJEON, South Korea, Aug. 2, 2022 /PRNewswire/ -- GenKOre, a biotech start-up in Korea, succeeded in the development of ABEs based on its own hypercompact gene-editing technology and had the relevant study published on Nature Chemical Biology onAugust 2, 2022.

2022-08-02 09:07 2026

Novel and fast typing method developed to control monkeypox by Molecular Biology Systems (MBS) in collaboration with the Amsterdam UMC and Danish Rigshospitalet

GOES, Netherlands, Aug. 2, 2022 /PRNewswire/ -- In the worldwide effort to control monkeypox, a novel and fast typing method to trace monkeypox virus strains was developed by Dutch company Molecular Biology Systems (MBS) in collaboration with the department of Medical Microbiology & Infectious Di...

2022-08-02 08:00 2000

Telix APAC Report: Regulatory Progress for Prostate and Kidney Cancer Imaging

MELBOURNE, Australia, Aug. 2, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today reports on regulatory progress for the Company's core prostate and kidney cancer imaging programs in theAsia Pacific (APAC) Operating Region, including progress in the major marke...

2022-08-02 06:54 1907

Pharming Group Receives Accelerated Assessment in Europe for leniolisib for the Treatment of Rare Immunodeficiency, APDS

EMA accelerated assessment allows a shorter review period for leniolisib from a standard 210 days to 150 days Pharming is on track to submit its Marketing Authorisation Application for leniolisib in H2 2022 LEIDEN, the Netherlands, Aug. 1, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or...

2022-08-01 13:00 2286

NeuroXess made the list of MIT Technology Review's TR50 for its silk-based minimally invasive implantable flexible brain-machine interface technology

WUXI, China, Aug. 1, 2022 /PRNewswire/ -- NeuroXess announced that it has been included in MIT Technology Review's list of the world's 50 smartest companies – the TR50 list – released onJuly 29 in Wuxi, China. NeuoXess was recognized mainly for its silk-enabled minimally invasive implantable high...

2022-08-01 12:40 1832

Active Motif and EpiCypher Execute Cross-Licensing Agreement and End Ongoing Litigation Involving Targeted Transposition/CUT&Tag Technology for Epigenomics

CARLSBAD, Calif. and RESEARCH TRIANGLE PARK, N.C., Aug. 1, 2022 /PRNewswire/ -- CUT&Tag is a targeted transposition technique that allows high-resolution genomic mapping of histone modifications and chromatin-associated proteins through the precise insertion of DNA sequences into the genome using...

2022-08-01 12:01 1607

Active Motif Incorporated Licenses Targeted Transposition to Diagenode S.A. Technology

CARLSBAD, Calif., Aug. 1, 2022 /PRNewswire/ -- Active Motif Incorporated, a company with the vision of bringing epigenetics more deeply into precision medicine, announced that it has non-exclusively licensed its foundational patents in transposition for use in CUT&Tag epigenetic assays to Diageno...

2022-08-01 11:30 1665

Innovent and Laekna Jointly Announce First Patient Dosed with Three-drug Combination in a Phase 1/2 Study for the Treatment of Patients with Solid Tumors Who Were Resistant to Prior Anti-PD-1/PD-L1 Therapy

SAN FRANCISCO and SUZHOU, China, Aug. 1, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, autoimmune, metabolic, ophthalmology and ot...

2022-08-01 08:00 2303

LIMES Randomised Controlled Trial about Sirolimus Coated Balloon in BTK takes the first Stride: patient enrolment started

Concept Medical Inc. , a pioneer in developing drug delivery device platforms for vascular intervention, has announced the initiation of LIMES trial. MÜNSTER, Germany, July 29, 2022 /PRNewswire/ -- LIMES (Prospective Multi-Center Randomized Controlled Trial to Ev...

2022-07-29 20:56 4813

As part of 'Operation Nasal Vaccine' to counter COVID-19 spread, ACM-001 booster vaccine administered to first subject in phase 1 safety and immunogenicity trial

SINGAPORE and BASEL, Switzerland and SYDNEY, July 29, 2022 /PRNewswire/ -- ACM Biolabs , a biotechnology company with operations in Singapore, Switzerland and Australia, focusing on the development of next generation vaccines for infectious diseases, personalized immunoth...

2022-07-29 16:00 2055

Angel Yeast Showcases Latest Innovation in Fermentation Nutrients at Bio China 2022

JINAN, China, July 28, 2022 /PRNewswire/ -- Angel Yeast (SH600298), a globally listed yeast and yeast extract manufacturer, exhibited its latest products and solutions of fermentation nutrients at Bio China 2022, an expo on fermentation and biotechnology held inJinan...

2022-07-28 20:48 3346

ILC Dover Announces Multi-compendial Water for Injection (WFI) for Growing Biotherapeutic and Cell & Gene Therapy Markets

NEWARK, Del., July 28, 2022 /PRNewswire/ -- ILC Dover LP ("ILC Dover" or the "Company"), specializing in innovative single-use solutions for biotherapeutics and pharmaceutical processing, announced the launch of Water for Injection (WFI) for the biotherapeutics market. Used for the preparation of...

2022-07-28 20:00 2120

Kira Pharmaceuticals Receives FDA Orphan Drug Designation for KP104, a Bifunctional Antibody Fusion Protein, for the Treatment of Paroxysmal Nocturnal Hemoglobinuria

CAMBRIDGE, Mass. and SUZHOU, China, July 28, 2022 /PRNewswire/ -- Kira Pharmaceuticals, a global clinical-stage biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Or...

2022-07-28 19:00 1890

Transcenta to Present Interim Safety and Efficacy Data of the TST001 and Chemotherapy Combination Expansion Cohort for Claudin18.2 Positive First Line Gastric Cancer at ESMO Congress 2022

SUZHOU, China, July 28, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that the interim safe...

2022-07-28 08:00 1829
1 ... 64656667686970 ... 167